DTC Advertising Harms Patients and Should Be Tightly Regulated

Donohue J. M. Cevasco M. and Rosenthal M. B. , “A Decade of Direct-to-Consumer Advertising of Prescription Drugs,” New England Journal of Medicine 357, no. 7 (2007): 673–681.

“Guidance for Industry: Consumer-Directed Broadcast Advertisements”, Food and Drug Administration, August 1999, available at <http://www.fda.gov/cder/guidance/1804fnl.htm> (last visited May 21, 2009).

Toop L. and Mangin D. , “Industry Funded Patient Information and the Slippery Slope to New Zealand,” British Medical Journal 335, no. 7622 (2007): 694–695.

Hollon M. F. , “Direct-to-Consumer Advertising: A Haphazard Approach to Health Promotion,” Journal of the American Medical Association 293, no. 16 (2005): 2030–2033.

National Institute for Health Care Management, “Prescription Drugs and Mass Media Advertising, 2000”, 2001, available at <http://www.nihcm.org/∼nihcmor/pdf/DTCbrief2001.pdf> (last visited May 22, 2009).

Graham D. J. Campen D. and Hui R. , “Risk of Acute Myocardial Infarction and Sudden Cardiac Death in Patients Treated with Cyclo-Oxygenase 2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs: Nested Case-Control Study,” The Lancet 365, no. 9458 (2005): 475–481.

Spence M. M. Teleki S. S. Cheetham T. C. Schweitzer S. O. and Millares M. , “Direct-to-Consumer Advertising of COX-2 Inhibitors: Effect on Appropriateness of Prescribing,” Medical Care Research and Review 62, no. 5 (2005): 544–559.

Bradford W. D. Kleit A. N. Nietert P. J. Steyer T. McIlwain T. and Ornstein S. , “How Direct-to-Consumer Television Advertising for Osteoarthritis Drugs Affects Physicians' Prescribing Behavior,” Health Affairs 25, no. 5 (2006): 1371–1377.

Galderma website, available at <http://www.differin.com/teens/index.shtml> (last visited May 21, 2009).

Wolfe S. M. , Letter to FDA Urging Action on Misleading CRESTOR Advertising by AstraZeneca (HRG Publication 1712), available at <http://www.citizen.org/publications/release.cfm?ID=7347> (last visited May 21, 2009).

Smith C. H. , Division of Drug Marketing, Advertising and Communications, Letter to Mark R. Szewczak, AstraZeneca, Food and Drug Administration, December 21, 2004, available at <http://www.fda.gov/cder/warn/2004/12779.pdf> (last visited May 22, 2009).

Saul S. , “Drug Ads Raise Questions for Heart Pioneer,” New York Times, February 7, 2008, at A1; Saul S. , “Pfizer to End Lipitor Ads by Jarvik,” New York Times, February 26, 2008, at C1.

Gollust S. E. Hull S. C. and Wilfond B. S. , “Limitations of Direct-to-Consumer Advertising for Clinical Genetic Testing,” Journal of the American Medical Association 288, no. 14 (2002): 1762–1767.

CyGene Direct website, available at <https://cygenedirect.com/athletic-performance/dna-testing-athletic-performance.html> (last visited May 22, 2009.)

Suracell website, available at <http://www.suracell.com/faqs/#1> (last visited May d, 2009).

General Accounting Office, “Prescription Drugs: FDA Oversight of Direct-to-Consumer Advertising has Limitations”, GA0-03-177, October 2002, available at <http://www.gao.gov/new.items/d03177.pdf> (last visited June 12, 2009).

Bell R. A. Kravitz R. L. and Wilkes M. S. , “Direct-to-Consumer Prescription Drug Advertising and the Public,” Journal of General Internal Medicine 14, no. 11 (1999): 651–657.

Aikin K. J. Swasy J. L. O. and Braman A. C. , “Patient and Physician Attitudes and Behaviors Associated with DTC Promotion of Prescription Drugs — Summary of FDA Survey Research Results”, Center for Drug Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services, November 19, 2004, available at <http://www.fda.gov/cder/ddmac/researchka.htm> (last visited May 22, 2009).

Id.

Kravitz R. L. Epstein R. M. and Feldman M. D. , “Influence of Patients' Requests for Direct-to-Consumer Advertised Antidepressants: A Randomized Controlled Trial,” Journal of the American Medical Association 293, no. 16 (2005): 1995–2002.

Mintzes B. Barer M. L. and Kravitz R. L. , “How Does Direct-to-Consumer Advertising (DTCA) Affect Prescribing? A Survey in Primary Care Environments With and Without Legal DTCA,” Canadian Medical Journal 169, no. 5 (2003): 405–412.

National Institute for Health Care Management, Prescription Drugs and Mass Media Advertising, September 2000, available at <http://www.nihcm.org/∼nihcmor/pdf/DTCbrief.pdf> (last visited May 22, 2009).

Henry J. Kaiser Family Foundation, “Impact of Direct-to-Consumer Advertising on Prescription Drug Spending”, 2003, available at <http://www.kff.org/rxdrugs/6084-index.cfm> (last visited May 22, 2009).

See General Accounting Office, supra note 16.

See Aikin , supra, note 18.

Gilbody S. Wilson P. and Watt I. , “Benefits and Harms of Direct to Consumer Advertising: A Systematic Review,” Quality & Safety in Health Care 14, no. 4 (2005): 246–250.

See Kravitz , supra, note 20.

Pharmaceutical Research and Manufacturers Association, “PhRMA Guiding Principles: Direct to Consumer Advertisements about Prescription Medicines”, 2005, available at <http://www.phrma.org/mediaroom/press/releases/02.08.2005.1195.cfm> (last visited May 22, 2009).

Sasich L. D. and Wolfe S. M. , “Deficiencies in Patient Information Leaflets Concerning Gastrointestinal Complications of Nonsteroidal Anti-Inflammatory Drugs,” Journal of General Internal Medicine 12, Supplement (1997): 79 (abstract); Bradley L. R. and Sasich L. D. , “The Information Content of Patient Medication Information Leaflets: Examination of Five Fluoroquinolone Antibiotics,” Journal of the American Pharmaceutical Association 38, no. 2 (1998): 278–279 (abstract); Wolfe S. M. and Sasich L. D. , “Comments before FDA Hearing on Current Status of Useful Written Prescription Drug Information for Consumers, July 31, 2003 (HRG Publication #1672), available at <http://www.citizen.org/publications/release.cfm?ID=7269> (last visited March 13, 2008).

Ingelfinger F. J. , “Advertising: Informational but Not Educational,” New England Journal of Medicine 286, no. 24 (1972): 1318–1319.

Food and Drug Administration, “Guidance for Industry: Consumer-Directed Broadcast advertisements,” Division of Drug Marketing, Advertising and Communications, 1999, available at <http://www.fda.gov/cder/guidance/1804fnl.htm> (last visited May 21, 2009); Food and Drug Administration, “Guidance for Industry: “Help-Seeking” and Other Disease Awareness Communications by or on Behalf of Drug and Device Firms”, Division of Drug Marketing, Advertising and Communications, 2004, available at <http://www.fda.gov/cder/guidance/6019dft.htm) (last visited May 22, 2009); Food and Drug Administration, “Guidance for Industry: Brief Summary: Disclosing Risk Information in Consumer-Directed Print Advertisements,” Division of Drug Marketing, Advertising and Communications, 2004, available at <http://www.fda.gov/cder/guidance/guidance.htm> (last visited May 22, 2009).

See General Accounting Office, supra note 16.

Anon , “FDA Enforcement Actions Against False and Misleading Prescription Drug Advertisements Declined in 2003”, Minority Staff of United States House of Representatives Committee on Government Reform, 2004, available at <http://www.democrats.reform.house.gov/story.asp?ID=440&Issue=Prescription+Drugs> (last visited May 22, 2009).

Division of Drug Marketing, Advertising and Communications, “Warning Letters and Notice of Violation Letters to Pharmaceutical Companies”, Food and Drug Administration, available at <http://www.fda.gov/cder/warn/index.htm> (last visited May 22, 2009).